This site is intended for healthcare professionals
  • Home
  • /
  • Clinical trials
  • /
  • Uncategorised Disease
  • /
  • A Study of Subcutaneous RoActemra/Actemra (Tociliz...
Clinical trial

A Study of Subcutaneous RoActemra/Actemra (Tocilizumab) in Patients With Active Rheumatoid Arthritis and Inadequate Response to Disease-Modifying Antirheumatic Drugs

Read time: 1 mins
Last updated:24th Jan 2014

This open-label, single-arm study will evaluate the safety, efficacy, and tolerability of subcutaneously administered RoActemra/Actemra (tocilizumab) in monotherapy or in combination with methotrexate (MTX) or other non-biologic disease-modifying antirheumatic drugs (DMARDs) in patients with active rheumatoid arthritis who are naïve to RoActemra/Actemra. Patients will receive RoActemra/Actemra 162 mg subcutaneously weekly for 24 weeks.

Category Value
Study start date 2014-01-24

View full details